LAPTM5 and neoplasm: High LAPTM5 expression is linked to the upregulation of immunosuppressive TOX pathway genes, CD8+ T cell exhaustion, and shorter overall survival of LUSC patients, suggesting that LAPTM5 may modulate tumor infiltration, antitumor immunity, and survival outcomes in LUSC patients [17].